Septerna (NASDAQ:SEPN) Stock Rating Lowered by Wall Street Zen

Septerna (NASDAQ:SEPN) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a note issued to investors on Saturday.

Several other brokerages also recently issued reports on SEPN. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Jones Trading began coverage on shares of Septerna in a research report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target for the company. Truist Financial assumed coverage on shares of Septerna in a research note on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $18.00 to $28.00 in a research report on Friday, November 14th. Finally, Raymond James Financial began coverage on shares of Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Septerna has an average rating of “Moderate Buy” and an average target price of $33.00.

Septerna Trading Down 1.7%

Shares of NASDAQ:SEPN opened at $25.30 on Friday. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -16.75 and a beta of 3.85. The business has a 50-day moving average price of $25.39 and a 200 day moving average price of $18.79. Septerna has a 12-month low of $4.17 and a 12-month high of $30.50.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The firm had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. As a group, equities research analysts predict that Septerna will post -7.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Daniel D. Long sold 3,501 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. The trade was a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new stake in shares of Septerna during the 3rd quarter worth approximately $36,000. Covestor Ltd raised its stake in Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after purchasing an additional 1,296 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after buying an additional 1,945 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in shares of Septerna during the second quarter worth approximately $107,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.